New diode laser-excitable green fluorescent label and its application to detection of bovine serum albumin via microchip electrophoresis

A novel amino-reactive fluorescent label is presented that is based on a yellow daylight chromophore and fluorophore. Its absorption band is wide and peaks at 431 nm in water solution, thus well matching the lines of either the 375-nm and the 431-nm diode lasers and of many frequency-variable dye lasers. When conjugated to bovine serum albumin (BSA), the fluorescence peaks at 501 nm with a quantum yield of 0.21. Its large Stokes' shift of 70 nm facilitates the discrimination of undesired excitation light which is particularly important for sensitive detection in miniaturized separation techniques such as microchip capillary electrophoresis (MCE). Unlike several other fluorophores, the fluorescence intensity of the new label is independent of pH over a broad range (3 to 9). The applicability of the label is demonstrated by labeling the amino acid lysine and the 66 kD protein BSA, and by separating BSA from the free label via MCE within 90 s. The limit of detection is in the order of 12 nM at an optically active path length of 20 µm

Evaluation of infartct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO 8Facilitated Intervention With Enhanced Reperfusion Speed to Events-Angiographic )study.

OBJECTIVES: The FINESSE-ANGIO (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events-Angiographic) study evaluated acute treatment effects on infarct-related artery (IRA) patency and angiographic correlates of coronary microcirculatory function. BACKGROUND: The FINESSE trial evaluated the effects on clinical outcomes of primary percutaneous coronary intervention (PCI) facilitated with pre-catheterization laboratory administration of abciximab with half-dose reteplase (combination-facilitated group), abciximab alone (abciximab-facilitated group), or with abciximab administered immediately before the procedure (primary PCI). METHODS: The FINESSE-ANGIO substudy compared the effects of the 3 treatment strategies on patency (TIMI [Thrombolysis In Myocardial Infarction] flow grade 2/3) of the IRA at basal coronary angiography. The secondary efficacy end points were corrected TIMI frame count, percentage of patients achieving TIMI flow grade 3, and the percentage achieving myocardial blush grade 2/3 of the IRA at post-PCI angiography. All angiographies were evaluated at a central core laboratory. RESULTS: Of the 2,452 FINESSE patients, 637 were included in the FINESSE-ANGIO substudy. Patients in the combination-facilitated group exhibited significantly higher rates of baseline IRA patency compared with the abciximab-facilitated and the primary PCI groups (76.1% vs. 43.7% and 32.7%, respectively; p < 0.0001 for both; p = 0.025 abciximab-facilitated vs. primary PCI). There were no significant differences in the post-PCI corrected TIMI frame count (17.1 ± 15.8, 17.4 ± 17.3, and 15.8 ± 14.1) or the rates of post-PCI TIMI flow grade 3 (79.8%, 77.7%, and 76.6%), myocardial blush grade 2/3 (85.6%, 79.5%, and 86.4%), respectively. CONCLUSIONS: Pre-catheterization laboratory administration of abciximab alone and especially in combination with half-dose reteplase resulted in higher rates of IRA patency at baseline coronary angiography compared with no pre-treatment. However, post-procedural angiographic and microcirculatory variables were unaffected by facilitation therapy